StemLife Berhad (Malaysia) – SECRETARIAT OF THE APCBBC
StemLife, the pioneer in private stem cell banking and therapeutics in Malaysia, offers storage for stem cells from newborns and adults. Established in 2001 with blessings from the Malaysian Government, StemLife was awarded the prestigious MSC status in 2002 and in 2006 the company was publicly-listed on the ACE Market (formerly known as MESDAQ). StemLife was granted the BioNexus status in 2007 and was certified in 2008 with the ISO 9001:2008 (UKAS & COFRAC).
StemLife, a licensed stem cell bank by the Malaysian Ministry of Health (under the Private Healthcare Facility and Services Act 1998), is the first and only private stem cell service provider in Malaysia to provide umbilical cord blood stem cells (UCBSC) for successful transplantation in paediatric leukaemia, thalassaemia and Cerebral Palsy (CP).
StemLife also process and store stem cells for adults and offer stem cell consultancy and therapeutic services, working closely with medical specialists to provide cost-efficient and personalized treatment. Current stem cell therapies available at StemLife are applications in oncology, haematology, heart disease, diabetic foot ulcers and sports and trauma injuries. StemLife’s international and local panel of advisors, comprising of doctors and scientists from five continents with expertise in haematology, obstetrics and gynaecology, oncology, pharmacology and pathology, also serve to keep StemLife on the forefront of stem cell therapeutic applications and the latest news.
StemLife operates its own 24-hour processing, testing and cryopreservation facility in KL which participates in stringent international external quality assurance and accreditation programs organized by the College of American Pathologists (CAP, USA). In accordance with international standards of stem cell banking, StemLife uses FDA-approved multi-compartmentalized stem cell storage systems for safe and secure long-term cryogenic storage. Equipped with clean room processing, its own pathogenic testing facilities and advanced secure storage areas, StemLife is the most comprehensive stem cell company in the country.
StemLife is also an active participant in R&D projects, and with close collaborations with leading hospitals and renowned specialists, it is ranked as one of the largest and most reputable stem cell companies in South East Asia.
http://www.StemLife.com
^ Back to Top
BIONET Corporation (Taiwan)
Established in 1999, BIONET Corp is a leading cell-tissue banking and therapy company in Asia. Their cord blood business unit, a well recognised brand known as “BabyBanks” is the first and largest private cord blood bank in Taiwan. Alongside this, BIONET also provides valuable services to establish the best practice in the industry. This includes the highly appraised donatable family banking program designed to balance the interests of public and private banking, a bank trust account service to manage operational risk, and a specialized logistic system to transport various types of tissues, cells and organs.
As the leader in the industry, BIONET is committed to providing the highest quality in collection, processing and cryopreservation of cord blood and the most integrated service for our customers. BIONET has two AABB accredited technical centres, respectively located in Northern and Southern Taiwan. These facilities meet the worldwide standard in the field of blood banking and cellular therapy.
http://www.BabyBanks.com
^ Back to Top
Cordlife Pte Ltd (Singapore) / PT. Cordlife (Indonesia)
CordLife collects, processes and stores stem cells which may later become potential source material for life-saving treatments.
Headquartered in Singapore, CordLife Ltd is the country's first private cord blood bank, incorporated in May 2001. Listed on the Australian Stock Exchange (ASX: CBB), the company currently operates three banks. Their laboratory in Singapore, where the cord blood samples are stored, is the first and only AABB-accredited facility in Southeast Asia. CordLife is also the first cord blood bank licensed by the Ministry of Health in Singapore. It also has a bank in Hong Kong, China, and in Sydney, Australia. Two more facilities are being built, in Kolkata, India, and in Jakarta, Indonesia.
With the rapid progress of stem cell research and development, other potential sources of adult stem cells such as adipose tissue and mesenchymal stem cells are expected to be found. Preliminary studies have already begun and CordLife is in the process of establishing international strategic alliances in these areas.
CordLife is a division of CyGenics, a biotechnology and immunotherapy company publicly-listed in Australia which focuses on development and commercialisation of adult stem cell-related products, services, applications and technologies.
http://www.cordlife.com
^ Back to Top
CryoLIFE (Hong Kong)
CRYOLIFE is the first Private Cord Blood Bank in Asia, and it is owned by Cell Therapy Technologies Centre Limited (CTTC), established in 1996. We believe in the potential of stem cell therapy in the field of reparative and regenerative medicine, and encouraged by the proliferation of successful cord blood transplants in the US, we decided to introduce the concept of saving cord blood to the local community. Our mission is to serve the community's needs in cord blood storage by providing the best-in-class cord blood collection, processing and storage services, and continuous improvement in cryopreservation technologies.
On 1 January 1998, CRYOLIFE was officially launched as the first family cord blood storage program in the Asian region. As an industry forerunner, we boast a few records which have set us apart from the competition. Now:
- We manage the largest cord blood inventory of over 15,000 units in Hong Kong,
- We are the first cord blood bank in Hong Kong accredited by the American Association of Blood Banks (AABB), the highest professional standard recognized by the industry worldwide,
- We are the first cord blood laboratory in Hong Kong practicing automation in processing which will maximize the recovery of mononuclear cells (MNCs) in cord blood processing,
- We have a dedicated transport team equipped with a temperature controlled cell safe to ensure the viability of client’s cord blood during transportation from the hospital to our laboratory.
In 2009, we take the lead to launch the CRYOmatch service and invest to set up a HLA Typing database (HLA stands for human leukocyte antigen). This service will ensure our customers and potential patients can have fast-action sample compatibility and matching, and improve the probability of successful transplant therapy; and eventually, it can help contributing to the application of cord blood to the community. In addition, in September 2009, Cryolife arranged the first patient from Hong Kong suffering from cerebral palsy to receive experimental treatment involving the transfusion of her own cord blood.
http://www.cryolife.com.hk
^ Back to Top
LIFECORD (Korea)
LIFECORD, established in 1997, is the first cord blood bank in Korea and Asia, adopting technology from the largest cord blood bank in the world - the US-based CBR. LIFECORD received a cord blood quality control certificate from the American Association of Blood Banks (AABB) as proof for its international recognition for storage technology.
LIFECORD R&D Center advances the development of various medications using cord blood stem cells. It undertakes continuous research into developing artificial organs and tissues and anti-cancerous immune cell medication. It has made patent applications in a range of countries.
LIFECORD’s core division CRO has signed a partnership with Pharma Service, a world-leading CRO corporation. LIFECORD’s CRO division is developing various new medications and new medical treatments under contract to a large range of clients. Their client base includes major pharmaceutical companies and medical organizations both nationally and internationally,
LIFECORD is renown within the national biomedicine industry for its global competitiveness and is continuously challenging the undeveloped medical industry. LIFECORD places its utmost priority on the enhancement of the Korean bio/life science industry to the extent that it can compete globally. Lifecord uses bold and active, but not reckless, marketing strategies.
http://company.lifecord.co.kr
^ Back to Top
Cryosite Ltd. (Australia)
Cryosite launched the first private cord blood service in 2001, operating with the necessary regulatory approval from the Therapeutic Goods Administration. They have successfully processed and stored cord blood collected by over 380 obstetricians in 200 hospitals throughout the country.
In 2002, the company expanded its range of services to include the provision of clinical logistics services to pharmaceutical companies and clinical research organizations, such as the Centre for Blood Therapies at the Peter MacCullum Institute in Melbourne which offers services to collect, process and cryopreserve adult blood stem cells until required for infusion. Cryosite also has an extensive local customer base of over 400 research institutions and biotechnology companies, developed through its role as exclusive distributor of American Type Culture Collection products to Australia and New Zealand.
The leading provider of specialist ultra-low temperature and cryogenic storage, Cryosite offers a service to manage and archive your biological samples in a secure, national repository. All staff have formal scientific qualifications and have an understanding of the high level of importance that needs to be associated with your samples. Their Quality Management System ensures detailed documentation control and compliance with all necessary regulations. Operations are carried out in a NATA accredited (ISO/IEC 17025) facility and are in compliance with current Code of Good Manufacturing Practices (cGMP). The facility is also AQIS approved under section 46a of the Quarantine Act for the quarantine of class 5.1 goods.
http://www.cryosite.com
^ Back to Top
StemCell Institute Ltd (Japan)
StemCell Institute was established in 1999, providing private banking of stem cells, research and development into new medical treatment methods utilising stem cells and the manufacture of medicines and medical instruments. With headquarters based in Tokyo, it also has sales branches covering the areas of Kinki, Kyushu, Tohoku and Nagoya. As of October 2010, the company recorded 20,500 units of stem cells stored for its clients.
http://www.stemcell.co.jp
^ Back to Top
THAI StemLife (Thailand)
THAI StemLife is the first private stem cell bank in Thailand with storage facilities in the country. It was founded in June 2005 and aimed to be the leading stem cell bank in Thailand by excelling industry standards and providing state-of-the-art comprehensive collection and banking services for stem cells in the umbilical cord blood and adult peripheral blood.
THAI StemLife was founded as a joint venture between Superior Biotech Co., Ltd., StemLife Bhd. Malaysia and Jetanin Hospital.
Superior Biotech Co., Ltd., THAI StemLife’s major business partner, is a private holding company with more than 50 leading private and government health care providers in the field of obstetrics and gynecology and infertility as well as within cardiology, paediatrics, haemato-oncology and transplantation.
StemLife Bhd. is the first Malaysian stem cell bank to be registered with the Ministry of Health and it is a business of strategic importance to Malaysia’s life science industry. With the Multimedia Development Corporation (MDC) as its strategic investment partner, StemLife Malaysia was awarded the prestigious MSC (Multimedia Super Corridor) status on March 31, 2002. StemLife Malaysia is also active in Indonesia and Sri Lanka and is currently listed on the KL Stock Exchange.
Jetanin Hospital is the leading ART/IVF Hospital in Thailand with more than 10 years of experience in cryopreservation.
Holders of preferred shares will include the National Innovation Agency at the Ministry of Science and Technology, a strong partner of THAI StemLife in research and development into cord blood stem cell expansion and stem cell treatment for heart disease and diabetic and atherosclerotic ulcers.
THAI StemLife has established state-of-the-art processing and development facilities in Bangkok, Thailand and has employed leading laboratory scientists to undertake its mission. More than 40 Hospitals in Thailand have trusted THAI StemLife with their samples.
http://www.thaistemlife.co.th
^ Back to Top
StemOne Biologicals (India)
StemOne Biologicals, a frontrunner stem cell company in India, was incorporated as Cord Life Biotech in 2005. Started its operations in 2006 and grown up the rate of 35-37% per annum. Cord Life Biotech came up with a new face, a new brand as StemOne in 2008.
We feel proud to announce StemOne, an organization catering every aspect of STEM cells under ONE roof to benefit human health.
The StemOne “triquetra” symbolizes the concept of integrated stem cell services wherein a client can utilize the three main arms of stem cells: long term preservation, cell based therapy for degenerative diseases and in house R&D.
Our efforts towards continual improvement in technological excellence with hands on service and personal attention have been recognized by an ISO 9000:2001 certification in Sep 2008.
With a promise of quality service, customer care and satisfaction, we are ready to be the next buzzword in the stem cell arena.
www.stemone.com
^ Back to Top
Lazaron Biotechnologies (SA) Ltd (South Africa)
Lazaron was established in 2004 as the first commercial South African biotech company to focus on the discovery, development and commercialisation of regenerative cell and medicine technologies. The primary business of the company is umbilical cord blood stem cell banking and the company was the first to introduce such a service on the African continent.
Lazaron is South Africa’s first and leading family umbilical cord blood stem cell bank with world class facilities situated in Cape Town, South Africa. We service South Africa, neighbouring countries, most sub-Saharan African countries including the Indian Ocean islands.
The company is currently expanding its technology platforms in collaboration with other international research institutions and has been granted the exclusive license for the storage of adult white blood cells, a relatively new service offering that has already been rolled out in the United States of America.
As preferred supplier to one of the largest hospital groups in South Africa, Lazaron aims to grow umbilical cord blood stem cell storage to a level of approximately 2% of the annual birth rate in South Africa within the next five years.
http://www.lazaron.co.za
^ Back to Top
Cell Safe Cord Blood Bank (Egypt)
At the end of year 2007 the death of one of the partner’s colleagues from leukemia due to failure of finding a matching stem cell donor, the idea of creating this service in Egypt was raised.
By 2009 the company created a law that was approved by the ministry of health in Egypt in order to allow private doctors to open a cord blood bank. The company is composed of a group of lab doctors as well as oby/gyn. They created this bank using the latest technology found worldwide in the field of cord blood separation and storage. The system used is a fully automated system both in separation and storage.
Cell safe bank is a private cord blood stem cell bank created based on the fact that Egypt suffers from leukemia cases among different age groups with no stem cell data base nor banking available and based on the fact that bone marrow transplantation (BMT) from HLA-identical sibling donors has been successfully utilized in the treatment of high-risk or recurrent hematological malignancies, bone marrow failure syndromes and selected hereditary immunodeficiency states and metabolic disorders we created the first private stem cell bank in Egypt.
Use of allogeneic BMT has been limited both by the lack of suitable donors, and because of the risk of life-threatening complications that arise when donor and recipient are not immunologically identical, namely, graft failure and graft-versus-host disease (GVHD).
In an attempt to increase the availability of suitable donors and reduce the morbidity and mortality associated with allogeneic bone marrow transplantation, clinical investigators worldwide have evaluated umbilical cord blood as an alternate source of hematopoietic stem and progenitor cells for transplantation.
In Egypt as the only licensed service available is the private family banking yet no public stem bank policy is introduced , cell safe has created the first private cord blood stem cell family bank as a start to introduce the concept of stem banking in order to make it routine practice and create later on a national stem cell bank with a HLA data base as the potential benefits of banked umbilical cord blood include: 1) absence of donor attrition, 2) rapid availability, and 3) minimal risk or inconvenience to the donor. Additional advantages which remain to be determined include: 1) low risk of transmissible infectious diseases, such as cytomegalovirus and Epstein-Barr virus, 2) lower risk of acute and chronic GVHD as compared to unrelated-donor marrow transplants, and 3) ability to tolerate HLA mismatched transplants.
http://cellsafebank.com
^ Back to Top
|
